Rydex Biotechnology Fund Class Investor
RYOIX
NASDAQ- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Rydex Biotechnology Fund Class Investor (RYOIX) is an open-end mutual fund that seeks capital appreciation by investing substantially all, or at least 80%, of its net assets in equity securities of biotechnology companies traded in the United States, as well as derivatives including futures contracts and options on securities, futures contracts, and stock indices; it focuses on companies engaged in biotechnology research and development, genetic or other biological engineering, and the design, manufacture, or sale of related biotechnology products or services, with significant exposure to small- and mid-sized capitalization biotechnology firms. The fund, which is non-diversified, primarily allocates to the health care sector (approximately 96%) and holds around 79-80 positions, including top holdings such as AbbVie Inc., Amgen Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Inc., and Regeneron Pharmaceuticals Inc.; it offers investor class shares with a net expense ratio of 1.39%-1.40%, portfolio turnover of 79%, and total net assets of approximately $81-117 million. Rydex Biotechnology Fund operates within the health industry segment, targeting institutional and retail investors seeking exposure to biotechnology equities, with geographic focus on U.S.-traded securities. Inception date April 1, 1998, the fund is managed by a team at Security Investors, LLC, a Guggenheim Partners affiliate, including long-tenured portfolio manager Michael Byrum (since 1998) alongside Adrian Bachman, Brendan Cain, Spencer Crane, and Scott Miller (each since July 2022); it is distributed by Guggenheim Funds Distributors, LLC, and previously associated with Rydex Funds. Recent developments include a most recent capital gain distribution of $9.4227-$9.422766 per share in 2025, alongside ongoing portfolio adjustments such as new positions in ADMA Biologics, Inc., reflecting active management amid biotechnology market dynamics; the fund maintains its core strategy with no reported acquisitions, mergers, or major strategic shifts for the Rydex Series Trust in the last 1-2 years, though it operates under Guggenheim Investments branding following prior Rydex integrations.